Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-384 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABT-384 | EXPERIMENTAL | - |
| Low dose ABT-384 | EXPERIMENTAL | - |
| Mid dose ABT-384 | EXPERIMENTAL | - |
| High dose ABT-384 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-384 | DRUG | Doses will be administered daily for 5 days. |
| Matching placebo to ABT-384 | DRUG | Doses will be administered daily for 21 days |
Inclusion Criteria: * Age is between 18 and 55 years * Judged to be in a condition of general good health based on the results of medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG Exclusion Criteria: * Use of protocol-prohibited medications within 2 weeks pr...
ABT-384 is an investigational small molecule drug developed by Abbott Laboratories. It is an inhibitor of the enzyme HSD11B1 and has been studied in Phase 1 clinical trials in healthy volunteers, including elderly subjects. Abbott Laboratories trades under the ticker ABT.
ABT-384 targets HSD11B1, also known as 11-beta-hydroxysteroid dehydrogenase type 1. It acts as an inhibitor of this enzyme. HSD11B1 is the molecular target of the drug, and its inhibition is the mechanism studied in the clinical program.
ABT-384 is developed by Abbott Laboratories, which trades under the ticker ABT. Abbott is the sponsor of the clinical trials conducted for this compound.
ABT-384 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, and no trials are currently active.
ABT-384 has been studied in two completed Phase 1 trials. NCT01009216 measured ABT-384 levels and pharmacodynamic activity in cerebrospinal fluid in 12 healthy male volunteers. NCT00968422 evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics in 28 elderly subjects aged 65 and older. Both trials were conducted in the United States.
The two completed Phase 1 trials of ABT-384 enrolled a total of 40 participants. NCT01009216 enrolled 12 healthy male volunteers, and NCT00968422 enrolled 28 elderly subjects. Both studies were randomized, double-blind, and placebo-controlled.